European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidates.","authors":"Natalie Jones, Trent M Schwartz, Steven Bishay, W Hudson Robb, Amanda Sams, Josh Kogan, Monica Nable, Sydney Nelson, Oliver S Zhao, Timothy Hohman, Steven Huang, Felipe Martinez, Ba Nguyen, Clifford Shin, Ming Yang, Holly Westervelt, Sarah M Szymkowicz, Lesley T Omary, Bashar A Aqel, Rolland Dickson, Blanca Lizaola, Amit Mathur, Manhal Izzy, Mary Ellen I Koran","doi":"10.1007/s00259-025-07382-0","DOIUrl":"10.1007/s00259-025-07382-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4652-4660"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).","authors":"Petra Petranović Ovčariček, Murat Tuncel, Michael C Kreissl, Alfredo Campennì, Bart de Keizer, Désirée Deandreis, Luca Giovanella","doi":"10.1007/s00259-025-07367-z","DOIUrl":"10.1007/s00259-025-07367-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4364-4367"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.","authors":"Christos Sachpekidis,Marina Hajiyianni,Martin Grözinger,Maja Piller,Annette Kopp-Schneider,Elias K Mai,Lukas John,Sandra Sauer,Niels Weinhold,Ekaterina Menis,Olof Enqvist,Marc S Raab,Anna Jauch,Lars Edenbrandt,Michael Hundemer,Alexander Brobeil,Johann Jende,Heinz-Peter Schlemmer,Stefan Delorme,Hartmut Goldschmidt,Antonia Dimitrakopoulou-Strauss","doi":"10.1007/s00259-025-07599-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07599-z","url":null,"abstract":"PURPOSEThe clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [1⁸F]FDG PET/CT.MATERIALS AND METHODSSeventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [18F]FDG PET/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the Medical Imaging Toolkit (MITK 2.4.0.0, Heidelberg, Germany) were used to quantify BM infiltration in the appendicular skeleton: (1) Manual approach, based on calculation of the highest mean CT value (CTv) within bony canals. (2) Semi-automated approach, based on summation of CT values across the appendicular skeleton to compute cumulative CT values (cCTv). PET/CT data were analyzed visually and via standardized uptake value (SUV) metrics, applying the Italian Myeloma criteria for PET Use (IMPeTUs). Additionally, an AI-based method was used to automatically derive whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from PET scans. Post-induction, all patients were evaluated for minimal residual disease (MRD) using BM multiparametric flow cytometry. Correlation analyses were performed between imaging data and clinical, histopathological, and cytogenetic parameters, as well as treatment response. Statistical significance was defined as p < 0.05.RESULTSAt baseline, the median CTv (manual) was 26.1 Hounsfield units (HU) and the median cCTv (semi-automated) was 5.5 HU. Both CT-based methods showed weak but significant correlations with disease burden indicators: CTv correlated with BM plasma cell infiltration (r = 0.29; p = 0.02) and β2-microglobulin levels (r = 0.28; p = 0.02), while cCTv correlated with BM plasma cell infiltration (r = 0.25; p = 0.04). Appendicular CT values further demonstrated significant associations with PET-derived parameters. Notably, SUVmax values from the BM of long bones were strongly correlated with both CTv (r = 0.61; p < 0.001) and moderately with cCTv (r = 0.45; p < 0.001). Patients classified as having increased [1⁸F]FDG uptake in the BM (Deauville Score ≥ 4), according to the IMPeTUs criteria, exhibited significantly higher CTv and cCTv values compared to those with Deauville Score <4 (p = 0.002 for both). AI-based analysis of PET data revealed additional weak-to-moderate significant associations, with MTV correlating with CTv (r = 0.32; p = 0.008) and cCTv (r = 0.45; p < 0.001), and TLG showing correlations with CTv (r = 0.36; p = 0.002) and cCTv (r = 0.46; p < 0.001). Following induction therapy, CT values decreased significantly from baseline (median CTv","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma.","authors":"Li-Ting Liu,Zhen-Chong Yang,Jia-Rui He,Hao-Xiang Long,Ying-Ying Hu,Jia-Yi Shen,Mei-Juan Luo,Yu-Chen Li,Xu Zhang,Su-Chen Li,Zi-Jian Lu,Bei-Bei Xiao,Jin-Hao Yang,Xiao-Fei Lv,Yu-Jing Liang,Shan-Shan Guo,Sai-Lan Liu,Xue-Song Sun,Xiao-Yun Li,Li Yuan,Liang-Ji Li,Guo-Dong Jia,Xue-Bin Xie,Kuok-Wai Iu,Wei Fan,Qiu-Yan Chen,Melvin L K Chua,Hai-Qiang Mai,Lin-Quan Tang","doi":"10.1007/s00259-025-07529-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07529-z","url":null,"abstract":"PURPOSEIn nasopharyngeal carcinoma (NPC), the 12-week period following radiotherapy (RT) represents a critical surveillance window for detecting residual disease and distant metastasis. We aim to assess the role of PET/CT And cfEBV DNA levels at 12 weeks post-RT in the surveillance of locoregionally advanced nasopharyngeal carcinoma (LA-NPC).METHODSPatients with stage III-IVa LA-NPC were included. PET/CT scans were conducted both pre-treatment And at 12 weeks post-RT. cfEBV DNA was assessed pre-treatment, at 4, 12, And 24 weeks post-RT, And subsequently at 3- to 6-month intervals. The primary endpoint was the negative predictive value (NPV) of 12-week PET/CT for identifying locoregional residual disease (RD) and/or distant metastasis (DM).RESULTSBetween 2018 And 2021, 506 eligible patients were prospectively enrolled (median follow-up: 45.2 months). At 12 weeks post-RT, RD was identified in 22 patients (4.3%), DM in 30 patients (5.9%), And both RD And DM in 6 patients (1.2%). For overall RD and/or DM, 12-week PET/CT demonstrated An NPV of 96.3%, sensitivity of 72.4%, specificity of 93.3%, positive predictive value (PPV) of 58.3%, And accuracy of 90.9%. The corresponding values for 12-week cfEBV DNA were An NPV of 91.7%, sensitivity of 41.7%, specificity of 34.5%, PPV of 93.8%, And accuracy of 87.0%. Among subgroups defined by 12-week cfEBV DNA levels, patients with undetectable cfEBV DNA showed a 96.8% NPV for PET/CT, whereas those with detectable cfEBV DNA demonstrated an 85.0% sensitivity for PET/CT.CONCLUSIONPET/CT performed at 12 weeks post-RT is a reliable tool for surveillance in LA-NPC, facilitating the optimization of follow-up strategies and enabling timely therapeutic interventions. The combined use of PET/CT and cfEBV DNA provides valuable risk-stratified insights for managing patients effectively.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"262 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative analysis of [18F]CHL2310, a novel PET ligand for cholesterol 24-Hydroxylase, in nonhuman primate brain.","authors":"Huiyi Wei,Junqi Hu,Achi Haider,Junjie Wei,Jie Ma,Hao Lu,Yuefeng Li,Yuanfang Jiang,Haige Yi,Huanyu Gong,Zhiqiang Tan,Jian Gong,Bin Guo,Xiaofei Zheng,Hao Xu,Hao Wang,Lu Wang","doi":"10.1007/s00259-025-07547-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07547-x","url":null,"abstract":"PURPOSECholesterol 24-hydroxylase (CYP46A1) is a brain-specific enzyme catalyzes the conversion of cholesterol into 24S-hydroxycholesterol, thereby playing a pivotal role in maintaining cerebral cholesterol homeostasis. Dysregulation of this pathway has been implicated in various neurological disorders, including Alzheimer's disease, Huntington's disease, epilepsy, and depression. To enable quantitative assessment of CYP46A1 activity in vivo, a CYP46A1-targeted PET radiotracer with high specificity and favorable pharmacokinetics is envisioned. This study aimed to evaluate the metabolic stability, target specificity, and pharmacokinetic properties of [18F]CHL2310, a novel CYP46A1 PET radioligand, in non-human primates.METHODS[18F]CHL2310 was synthesized using a tosylate precursor. Baseline and TAK-935 pre-blocked PET imaging with arterial blood sampling were performed in non-human primates. Whole-blood and plasma radioactivity, plasma free fraction, and metabolite analysis were conducted to generate metabolite-corrected plasma input functions. Regional brain time-activity curves were fitted using one-tissue compartment model, two-tissue compartment model and Logan graphical analysis to estimate total distribution volume. CYP46A1 occupancy by TAK-935 was quantified using Lassen plots, enabling the assessment of the dose-occupancy relationship. Non-displaceable binding potential was calculated using either non-displaceable distribution volume or the cerebellum as a reference region. Test-retest variability was evaluated in baseline scans from the same subject. Additionally, whole-body PET imaging was performed in male and female monkeys to estimate human radiation dosimetry.RESULTS[18F]CHL2310 was synthesized with a non-decay-corrected radiochemical yield of 6.7 ± 1.5% and radiochemical purity >99%. The tracer demonstrated high specific binding in NHP brain with reasonable metabolic stability and a free fraction of 13.1 ± 0.8% in plasma. TACs were well described by two-tissue compartment model and Logan graphical analysis. TAK-935 exhibited dose-dependent CYP46A1 occupancy with a half-maximal inhibitory dose of 0.0095 mg/kg, derived from Lassen plots. The averaged test-retest variability of tissue distribution volumes was -3.0 ± 4.8%, and the averaged absolute TRV was 4.4 ± 3.5%. The effective radiation dose for humans was estimated as 0.013 mSv/MBq.CONCLUSION[18F]CHL2310 shows high in vivo specificity, favorable pharmacokinetic properties, and robust quantitative performance in non-human primates. These characteristics support its potential as a PET radiotracer for imaging CYP46A1 in human studies.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"29 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose metabolism in hyper-connected regions predicts neurodegeneration and speed of conversion in Alzheimer's disease.","authors":"Alice Galli, Marianna Inglese, Luca Presotto, Rachele Malito, Xin Di, Nicola Toschi, Andrea Pilotto, Alessandro Padovani, Cristina Tassorelli, Daniela Perani, Arianna Sala, Silvia Paola Caminiti","doi":"10.1007/s00259-025-07379-9","DOIUrl":"10.1007/s00259-025-07379-9","url":null,"abstract":"<p><strong>Purpose: </strong>Here, we combined a longitudinal design to assess whole-brain hyper- and hypo-connectivity in the different clinical phases of Alzheimer's disease (AD) with a multimodal approach to understand how such connectivity changes were related to glucose hypometabolism.</p><p><strong>Methods: </strong>We selected a longitudinal cohort of N = 66 subjects with clinical, cerebrospinal fluid and FDG-PET assessments, from Alzheimer's Disease Neuroimaging Initiative (ADNI) database. N = 31 AD individuals were assessed at three stages: mild cognitive impairment (AD-MCI, T0), early phase of dementia (mild-AD, T1) and dementia (AD-D, T2). We included N = 35 age/sex-matched healthy controls. We assessed longitudinal metabolic connectivity using Pearson's correlation, clustering analysis and graph theory metrics.</p><p><strong>Results: </strong>In the MCI-AD stages, hypo- and hyper-connectivity coexisted. Data-driven, longitudinal clustering analysis identified specific pathological clusters: a default mode network cluster, with prevalent hypo-connectivity and severe, persistent hypometabolism; a limbic cluster showing hyper-connectivity and steeper metabolic decline. Metabolism in hyper-connected limbic regions showed a mediation effect on worsening of AD-like parieto-temporal hypometabolism and predicted faster conversion to dementia.</p><p><strong>Conclusion: </strong>Hypo- and hyper-connectivity, especially in early stages, may have different roles in AD neurodegenerative processes, with metabolism in hyper-connected regions acting as a mediator on the neurodegeneration of core regions of AD pathology.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4639-4651"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.","authors":"Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Lisbeth Marner, Ian Law, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks","doi":"10.1007/s00259-025-07377-x","DOIUrl":"10.1007/s00259-025-07377-x","url":null,"abstract":"<p><strong>Purpose: </strong>PET using the radiolabeled amino acid O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine ([¹⁸F]FET) has considerable clinical value for follow-up evaluation of central nervous system tumors in children and adolescents. As medical procedures must be justified socio-economically, we determined cost-effectiveness of [¹⁸F]FET PET for identification of treatment-related changes.</p><p><strong>Methods: </strong>We analyzed clinical data from two different studies that assessed the value of FET PET to differentiate between brain and spinal tumor relapse and treatment-related changes in children and adolescents. Cost calculation was based on the German statutory health insurance system perspective. Due to subtle differences in the diagnostic approach of the studies, two separate clinical scenarios including 80 patients with 105 lesions were considered: Decision tree model 1 determined cost-effectiveness of simultaneous [¹⁸F]FET PET and MRI in comparison to MRI alone to identify treatment-related changes. Decision tree model 2 determined cost-effectiveness of [¹⁸F]FET PET alone to identify treatment-related changes when routine MRI findings were suspicious for tumor relapse. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.</p><p><strong>Results: </strong>Model 1 revealed that the rate of identified treatment-related changes increased by 52% when adding [¹⁸F]FET PET to MRI, resulting in costs of €3,314.51 for each additional correctly identified lesion with treatment-related changes by [¹⁸F]FET PET that MRI would have misclassified. Model 2 revealed that [¹⁸F]FET PET correctly identified treatment-related changes in 90% of lesions when routine MRI findings were suspicious for tumor relapse, resulting in costs of €1,740.37 for each lesion.</p><p><strong>Conclusion: </strong>Integrating [¹⁸F]FET PET in the follow-up of in children and adolescents with brain and spinal tumor may help improving patient care at acceptable costs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4616-4626"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey.","authors":"Maximilian J Mair, Philipp Lohmann, Norbert Galldiks, Mattias Belting, Petter Brandal, Martinus P G Broen, Francesco Cicone, Jean-François Daisne, François Ducray, Felix Ehret, Julia Furtner, Asgeir S Jakola, Maximilian Niyazi, Alessia Pellerino, Marika Rasschaert, Evangelia Razis, Felix Sahm, Marion Smits, Nelleke Tolboom, Antoine Verger, Emilie Le Rhun, Giuseppe Minniti, Michael Weller, Matthias Preusser, Nathalie L Albert","doi":"10.1007/s00259-025-07366-0","DOIUrl":"10.1007/s00259-025-07366-0","url":null,"abstract":"<p><strong>Purpose: </strong>Positron emission tomography (PET) is increasingly used in neuro-oncology. However, little is known about its application across European institutions and reasons for variable implementation.</p><p><strong>Methods: </strong>Between June and August 2024, members of the European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) completed a cross-sectional online survey on PET use in neuro-oncological practice.</p><p><strong>Results: </strong>Overall, 103 replies from 20 countries were received. A PET facility was available at 96/103 (93.2%) sites, of whom 74 (77.1%) performed PET in patients with brain tumours. Reasons for not performing PET included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET perceived unnecessary (8/29, 27.6%). Of sites performing PET, 69/74 (93.2%) reported use in glioma, 58/74 (78.4%) in brain metastasis, 52/74 (70.3%) in meningioma, and 46/74 (62.2%) in CNS lymphoma. Amino acid PET was performed at 62/71 centres (87.3%; 3 not reported [n.r.]), most frequently in glioma (58/59, 98.3%, 3 n.r.) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%, 6 n.r.), mainly in meningioma (48/49, 98.0%), for patient selection before radioligand therapy (41/49, 83.7%) and for radiotherapy target volume definition (33/49, 67.3%). Unrestricted coverage by statutory health insurance was reported by 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET.</p><p><strong>Conclusion: </strong>PET use in neuro-oncology is variable across EORTC-BTG sites. Generation of evidence in clinical trials and surveys including non-academic institutions are needed to guide implementation in clinical practice.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4627-4638"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies.","authors":"Nalan Alan Selcuk,Gamze Beydagi,Kaan Akcay,Ayşegul Gormez,Turkay Toklu,Levent Kabasakal","doi":"10.1007/s00259-025-07597-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07597-1","url":null,"abstract":"OBJECTIVEThis study aimed to investigate the potential efficacy of [⁶⁸Ga]Ga-FAP-2286 PET/CT in evaluating treatment response in patients with gastrointestinal system malignancies.MATERIALS AND METHODSPatients with histopathologically confirmed gastrointestinal malignancies who underwent [⁶⁸Ga]Ga-FAP-2286 PET/CT for treatment response assessment between November 2020 and January 2025 were included. All images were evaluated by three experienced nuclear medicine physicians. The maximum standardized uptake values (SUVmax), total tumor volumes, and total lesion FAP expression values of primary tumors and metastases were recorded. At the same time, serum tumor marker levels were analyzed. Imaging responses were assessed separately according to PERCIST criteria on [⁶⁸Ga]Ga-FAP-2286 PET/CT and RECIST criteria on CT. Survival outcomes were analyzed using the Kaplan-Meier method, and their association with treatment response on [⁶⁸Ga]Ga-FAP-2286 PET/CT was assessed using the Log-Rank (Mantel-Cox) test and Cox proportional hazards regression. A p-value &lt; 0.05 was considered statistically significant in all analyses.RESULTSA total of 100 [⁶⁸Ga]Ga-FAP-2286 PET/CT scans were performed in 50 patients (mean age: 61.62 ± 12.95), both before and after treatment. Among the included patients, 70% had gastric cancer, 14% had colon cancer, 8% had pancreatic cancer, 4% had appendiceal cancer, 2% had hepatocellular carcinoma (HCC), and 2% had cholangiocellular carcinoma. Primary/recurrent tumor lesions were observed in 62% of patients, lymph node metastases in 24%, visceral metastases in 10%, peritoneal metastases in 76%, and bone metastases in 14%. A strong correlation was found between tumor volumes and total lesion FAP expression measured by [⁶⁸Ga]Ga-FAP-2286 PET/CT and the corresponding serum tumor markers (Area Under the Curve [AUC] for delta tumor volume and total lesion FAP expression = 0.875). There was a statistically significant and near-perfect concordance between [⁶⁸Ga]Ga-FAP-2286 PET PERCIST and CT RECIST criteria (Kappa = 0.833, p &lt; 0.05). Moderate agreement was found for primary tumors (Kappa = 0.526, p &lt; 0.05) and bone metastases (Kappa = 0.657, p &lt; 0.05), while excellent agreement was observed for lymph node (Kappa = 1.0, p &lt; 0.05), peritoneal (Kappa = 0.815, p &lt; 0.05), and visceral metastases (Kappa = 1.0, p &lt; 0.05). According to the Kaplan-Meier analysis, treatment response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival (p = 0.02). Median overall survival was 7.6 months in patients with progressive disease and 19.8 months in those with stable disease, as defined by PERCIST criteria. Median survival was not reached in patients showing partial or complete response.CONCLUSIONIn gastrointestinal system malignancies, a strong correlation was observed between serum tumor markers and both total tumor volumes and total lesion FAP expression values derived from [⁶⁸Ga]Ga-FAP-2286 PET imaging. Additionally, molecular response assessed b","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive LGE and FDG/PYP uptake mimicking infiltrative disease: A case of triple-vessel coronary artery disease.","authors":"Keiko Takahashi-Hayashi,Osamu Manabe,Hideo Fujita,Noriko Oyama-Manabe","doi":"10.1007/s00259-025-07566-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07566-8","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"67 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}